Eicosapentaenoic acid administration ameliorates the progression of liver fibrosis after laparoscopic Kasai portoenterostomy
Pediatric Surgery International · 2024
DOI: 10.1007/s00383-024-05800-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Surgery International, 2024. Verfasst von Wataru Sumida und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Surgery, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, 466-8550, Japan. wsumida@med.nagoy…. Hauptthemen laut MEDLINE: Portoenterostomy, Hepatic, Liver Cirrhosis, Eicosapentaenoic Acid, Biliary Atresia. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Nagoya University.
Abstract (Originalsprache)
Purpose
Biliary atresia (BA) poses a persistent challenge characterized by ongoing liver inflammation and subsequent fibrosis even after the clearance of jaundice (COJ). This study aimed to evaluate the therapeutic potential of eicosapentaenoic acid (EPA) in alleviating liver inflammation and limiting fibrosis during the post-COJ phase of BA.
Methods
Among the BA patients undergoing laparoscopic Kasai portoenterostomy (lapKP) between December 2016 and October 2021, EPA (20–40 mg/kg/day) was administered orally to those whose parents consented. The study included patients from January 2014 to October 2021, classifying them into two groups: EPA-treated (Group E) and untreated (Group N). Their liver fibrosis and clinical course at 1 and 2 years post-lapKP were compared.
Results
Group E consisted of 25 patients, while Group N comprised 32 patients. Twenty-one patients in Group E and 25 patients in Group N achieved COJ ( p = 0.74). Among jaundice-free patients at 1 and 2 years post-lapKP, Group E exhibited significantly lower M2BPGi levels and platelet counts, and Group E showed a significant reduction in Aminotransferase-to-Platelet Ratio Index (APRI) at 2 years post-lapKP.
Conclusion
Although EPA administration did not improve COJ, it attenuated the progression of liver fibrosis during the 2 years following lapKP in jaundice-free patients. (200/200Words).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatric Surgery, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, 466-8550, Japan. wsumida@med.nagoya-u.ac.jp.
- Department of Pediatric Surgery, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, 466-8550, Japan.
Förderung
- Nagoya University
Zitieren
APA
Sumida, W., Tainaka, T., Shirota, C., Makita, S., Amano, H., Yasui, A., Maeda, T., Kato, D., Goda, Y., Ishii, H., Ota, K., Yaohui, G., Jiahui, L., Hinoki, A., & Uchida, H. (2024). Eicosapentaenoic acid administration ameliorates the progression of liver fibrosis after laparoscopic Kasai portoenterostomy. Pediatric Surgery International. https://doi.org/10.1007/s00383-024-05800-2
Vancouver
Sumida W, Tainaka T, Shirota C, Makita S, Amano H, Yasui A, et al. Eicosapentaenoic acid administration ameliorates the progression of liver fibrosis after laparoscopic Kasai portoenterostomy. Pediatric Surgery International. 2024. doi:10.1007/s00383-024-05800-2
BibTeX
@article{Sumida2024,
author = {Sumida, Wataru and Tainaka, Takahisa and Shirota, Chiyoe and Makita, Satoshi and Amano, Hizuru and Yasui, Akihiro and Maeda, Takuya and Kato, Daiki and Goda, Yosuke and Ishii, Hiroki and Ota, Kazuki and Yaohui, Guo and Jiahui, Liu and Hinoki, Akinari and Uchida, Hiroo},
title = {Eicosapentaenoic acid administration ameliorates the progression of liver fibrosis after laparoscopic Kasai portoenterostomy},
journal = {Pediatric Surgery International},
year = {2024},
doi = {10.1007/s00383-024-05800-2}
}
EUVIMED